{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:29:28Z","timestamp":1793874568604,"version":"4.6.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2023 PROD 00134"],"award-info":[{"award-number":["2023 PROD 00134"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23\/01537"],"award-info":[{"award-number":["PI23\/01537"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biofilm"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bioflm.2026.100400","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:08:42Z","timestamp":1789502922000},"page":"100400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The activity of a new bicyclic peptide, PLP-3, against colistin-resistant Pseudomonas aeruginosa biofilms"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7911-2085","authenticated-orcid":false,"given":"N\u00faria","family":"Mart\u00edn-Vilardell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa","family":"Higazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Ballest\u00e9-Delpierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8025-3926","authenticated-orcid":false,"given":"Jordi","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"H\u00f8iby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Ciofu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioflm.2026.100400_bib1","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1164\/rccm.200408-1044SO","article-title":"Pathogen\u2013host interactions in Pseudomonas aeruginosa pneumonia","volume":"171","author":"Sadikot","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bioflm.2026.100400_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2217\/17460913.1.1.53","article-title":"Cystic fibrosis: a polymicrobial infectious disease","volume":"1","author":"Sibley","year":"2006","journal-title":"Future Microbiol"},{"key":"10.1016\/j.bioflm.2026.100400_bib3","unstructured":"Cystic fibrosis foundation [WWW Document], n.d. URL https:\/\/www.cff.org\/(accessed December.19.2025)."},{"key":"10.1016\/j.bioflm.2026.100400_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.bioflm.2026.100400_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-1172-7-14","article-title":"Evidence for decline in the incidence of cystic fibrosis: a 35-year observational study in Brittany, France","volume":"7","author":"Scotet","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.bioflm.2026.100400_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s44259-024-00060-5","article-title":"Polymicrobial infection in cystic fibrosis and future perspectives for improving Mycobacterium abscessus drug discovery","volume":"2","author":"Baker","year":"2024","journal-title":"Npj Antimicrob Resist"},{"key":"10.1016\/j.bioflm.2026.100400_bib7","series-title":"WHO bacterial priority pathogens list 2024: bacterial pathogens of public health importance, to guide research, development, and strategies to prevent and control antimicrobial resistance","year":"2024"},{"key":"10.1016\/j.bioflm.2026.100400_bib8","first-page":"1527","article-title":"Biofilm formation of Pseudomonas aeruginosa in cystic fibrosis: mechanisms of persistence","volume":"13","author":"Borisova","year":"2025","journal-title":"Adaptation, and Pathogenesis"},{"key":"10.1016\/j.bioflm.2026.100400_bib9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3389\/fmicb.2019.00913","article-title":"Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents\u2014how P. aeruginosa can escape antibiotics","volume":"10","author":"Ciofu","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bioflm.2026.100400_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuad060","article-title":"Pseudomonas aeruginosa biofilm exopolysaccharides: assembly, function, and degradation","volume":"47","author":"Gheorghita","year":"2023","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.bioflm.2026.100400_bib11","doi-asserted-by":"crossref","first-page":"8671","DOI":"10.3390\/ijms21228671","article-title":"Pseudomonas aeruginosa biofilms","volume":"21","author":"Thi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bioflm.2026.100400_bib12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3389\/fmicb.2019.00677","article-title":"Confocal laser scanning microscopy for analysis of Pseudomonas aeruginosa biofilm architecture and matrix localization","volume":"10","author":"Reichhardt","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bioflm.2026.100400_bib13","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/1462-2920.12155","article-title":"The extracellular matrix protects Pseudomonas aeruginosa biofilms by limiting the penetration of tobramycin","volume":"15","author":"Tseng","year":"2013","journal-title":"Environ Microbiol"},{"key":"10.1016\/j.bioflm.2026.100400_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrmicro1838","article-title":"Physiological heterogeneity in biofilms","volume":"6","author":"Stewart","year":"2008","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bioflm.2026.100400_bib15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/1469-0691.12651","article-title":"Antimicrobial susceptibility testing in biofilm-growing bacteria","volume":"20","author":"Macia","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bioflm.2026.100400_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1128\/AAC.47.1.317-323.2003","article-title":"Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin","volume":"47","author":"Walters","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bioflm.2026.100400_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioflm.2019.100018","article-title":"Forming and waking dormant cells: the ppGpp ribosome dimerization persister model","volume":"2","author":"Wood","year":"2020","journal-title":"Biofilm"},{"key":"10.1016\/j.bioflm.2026.100400_bib18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3390\/antibiotics14050526","article-title":"Combatting Pseudomonas aeruginosa with \u03b2-Lactam antibiotics: a revived weapon?","volume":"14","author":"Zhao","year":"2025","journal-title":"Antibiotics"},{"key":"10.1016\/j.bioflm.2026.100400_bib19","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1128\/MMBR.00013-14","article-title":"Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics","volume":"78","author":"Lebeaux","year":"2014","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.bioflm.2026.100400_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijantimicag.2004.10.001","article-title":"Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria","volume":"25","author":"Li","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bioflm.2026.100400_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jcf.2008.02.003","article-title":"Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients","volume":"7","author":"Johansen","year":"2008","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.bioflm.2026.100400_bib22","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","article-title":"Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing","volume":"30","author":"Lim","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bioflm.2026.100400_bib23","article-title":"Prevalence of colistin resistance in clinical isolates of Pseudomonas aeruginosa: a systematic review and meta-analysis","volume":"15","author":"Narimisa","year":"2024","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bioflm.2026.100400_bib24","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1099\/00221287-146-10-2543","article-title":"Role of Pseudomonas aeruginosa PhoP-PhoQ in resistance to antimicrobial cationic peptides and aminoglycosides","volume":"146","author":"Macfarlane","year":"2000","journal-title":"Microbiology"},{"key":"10.1016\/j.bioflm.2026.100400_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/mra.00558-25","article-title":"Genome sequences of two highly colistin-resistant Pseudomonas aeruginosa clinical isolates from the cystic fibrosis lung","volume":"14","author":"Mattingly","year":"2025","journal-title":"Microbiol Resour Announc"},{"key":"10.1016\/j.bioflm.2026.100400_bib26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1128\/JB.186.2.575-579.2004","article-title":"PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A","volume":"186","author":"Moskowitz","year":"2004","journal-title":"J Bacteriol"},{"key":"10.1016\/j.bioflm.2026.100400_bib27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-014-0181-0","article-title":"Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"74","author":"Conole","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.bioflm.2026.100400_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01641-22","article-title":"Colistin enhances Rifampicin's antimicrobial action in colistin-resistant Pseudomonas aeruginosa biofilms","volume":"67","author":"Armengol","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bioflm.2026.100400_bib29","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1093\/jac\/dkac284","article-title":"A new synthetic protegrin as a promising peptide with antibacterial activity against MDR Gram-negative pathogens","volume":"77","author":"Moreno-Morales","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bioflm.2026.100400_bib30","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1128\/JCM.42.5.1915-1922.2004","article-title":"Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis","volume":"42","author":"Moskowitz","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bioflm.2026.100400_bib31","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1600-0463.2007.apm_630.x","article-title":"Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci","volume":"115","author":"Stepanovi\u0107","year":"2007","journal-title":"APMIS"},{"key":"10.1016\/j.bioflm.2026.100400_bib32","series-title":"Microbial biofilms: methods and protocols, methods in molecular biology","first-page":"239","article-title":"Pharmacokinetics and pharmacodynamics of antibiotics in biofilm infections of Pseudomonas aeruginosa in vitro and In Vivo","author":"Wang","year":"2014"},{"key":"10.1016\/j.bioflm.2026.100400_bib33","series-title":"Pseudomonas methods and protocols, methods in molecular biology","first-page":"615","article-title":"Methods for studying biofilm formation: flow cells and confocal laser scanning microscopy","author":"Tolker-Nielsen","year":"2014"},{"key":"10.1016\/j.bioflm.2026.100400_bib34","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1128\/JB.01515-06","article-title":"Multiple roles of biosurfactants in structural biofilm development by Pseudomonas aeruginosa","volume":"189","author":"Pamp","year":"2007","journal-title":"J Bacteriol"},{"key":"10.1016\/j.bioflm.2026.100400_bib58","series-title":"Pseudomonas methods and protocols, methods in molecular biology","year":"2014"},{"key":"10.1016\/j.bioflm.2026.100400_bib35","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00430-019-00624-7","article-title":"In vitro activity of Protegrin-1, alone and in combination with clinically useful antibiotics, against Acinetobacter baumannii strains isolated from surgical wounds","volume":"208","author":"Morroni","year":"2019","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.bioflm.2026.100400_bib36","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00253-021-11103-6","article-title":"Antibiofilm peptides as a promising strategy: comparative research","volume":"105","author":"Li","year":"2021","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.bioflm.2026.100400_bib37","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1021\/acsomega.8b00483","article-title":"Insights into membrane translocation of protegrin antimicrobial peptides by multistep molecular dynamics simulations","volume":"3","author":"Lai","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioflm.2026.100400_bib38","doi-asserted-by":"crossref","first-page":"11000","DOI":"10.3390\/ijms130911000","article-title":"Multiscale models of the antimicrobial peptide Protegrin-1 on gram-negative bacteria membranes","volume":"13","author":"Bolintineanu","year":"2012","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bioflm.2026.100400_bib39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3390\/ph18030289","article-title":"Protegrin-1 and analogues against Acinetobacter baumannii: a narrative review","volume":"18","author":"Rizzetto","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioflm.2026.100400_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioflm.2022.100089","article-title":"Interplay between biofilm microenvironment and pathogenicity of Pseudomonas aeruginosa in cystic fibrosis lung chronic infection","volume":"4","author":"Guillaume","year":"2022","journal-title":"Biofilm"},{"key":"10.1016\/j.bioflm.2026.100400_bib41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2958.2008.06152.x","article-title":"Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB\u2010oprM genes","volume":"68","author":"Pamp","year":"2008","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.bioflm.2026.100400_bib42","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/IDR.S238811","article-title":"Prevalence and some possible mechanisms of Colistin resistance among multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa","volume":"13","author":"Abd El-Baky","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.bioflm.2026.100400_bib43","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/jps.20627","article-title":"In vitro hemolysis: guidance for the pharmaceutical scientist","volume":"95","author":"Amin","year":"2006","journal-title":"J Pharmaceut Sci"},{"key":"10.1016\/j.bioflm.2026.100400_bib44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1006\/excr.1998.4172","article-title":"Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism","volume":"243","author":"Foster","year":"1998","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.bioflm.2026.100400_bib45","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/antibiotics9120880","article-title":"Antimicrobial susceptibility testing in Pseudomonas aeruginosa biofilms: one step closer to a standardized method","volume":"9","author":"Lozano","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.bioflm.2026.100400_bib46","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1093\/jac\/dkab222","article-title":"Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates","volume":"76","author":"D\u00edez-Aguilar","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bioflm.2026.100400_bib47","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14787210.2018.1441024","article-title":"Murepavadin: a new antibiotic class in the pipeline","volume":"16","author":"Martin-Loeches","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.bioflm.2026.100400_bib48","doi-asserted-by":"crossref","first-page":"9050","DOI":"10.1021\/acs.jmedchem.2c00270","article-title":"Antimicrobial peptides against multidrug-resistant Pseudomonas aeruginosa biofilm from cystic fibrosis patients","volume":"65","author":"Ben Hur","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioflm.2026.100400_bib49","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3390\/antibiotics3040509","article-title":"Anti-biofilm and immunomodulatory activities of peptides that inhibit biofilms formed by pathogens isolated from cystic fibrosis patients","volume":"3","author":"De La Fuente-N\u00fa\u00f1ez","year":"2014","journal-title":"Antibiotics"},{"key":"10.1016\/j.bioflm.2026.100400_bib50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fmicb.2019.00275","article-title":"Antimicrobial activity of \u03b1-Peptide\/\u03b2-Peptoid lysine-based peptidomimetics against colistin-resistant Pseudomonas aeruginosa isolated from cystic fibrosis patients","volume":"10","author":"Molchanova","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bioflm.2026.100400_bib51","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1128\/AAC.00918-12","article-title":"Identification of peptides derived from the human antimicrobial peptide LL-37 active against biofilms formed by Pseudomonas aeruginosa using a library of truncated fragments","volume":"56","author":"Nagant","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bioflm.2026.100400_bib52","first-page":"145","volume":"vol. 12","author":"Pompilio","year":"2012"},{"key":"10.1016\/j.bioflm.2026.100400_bib53","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.peptides.2011.08.002","article-title":"Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients","volume":"32","author":"Pompilio","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.bioflm.2026.100400_bib54","article-title":"Antibiofilm activities of borneol-citral-loaded pickering emulsions against Pseudomonas aeruginosa and Staphylococcus aureus in physiologically relevant chronic infection models","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.bioflm.2026.100400_bib55","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1086\/656788","article-title":"Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa","volume":"202","author":"Herrmann","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bioflm.2026.100400_bib56","article-title":"Engineered lipid nanoparticles loaded with LL-37 peptide as inhalable drug delivery carriers for the treatment of bacterial infections","volume":"176","author":"Reczy\u0144ska-Kolman","year":"2025","journal-title":"Biomater Adv"},{"key":"10.1016\/j.bioflm.2026.100400_bib57","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijpharm.2015.07.001","article-title":"Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis","volume":"491","author":"Kwok","year":"2015","journal-title":"Int J Pharm"}],"container-title":["Biofilm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590207526000572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590207526000572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:01:58Z","timestamp":1793872918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590207526000572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":58,"alternative-id":["S2590207526000572"],"URL":"https:\/\/doi.org\/10.1016\/j.bioflm.2026.100400","relation":{},"ISSN":["2590-2075"],"issn-type":[{"value":"2590-2075","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The activity of a new bicyclic peptide, PLP-3, against colistin-resistant Pseudomonas aeruginosa biofilms","name":"articletitle","label":"Article Title"},{"value":"Biofilm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioflm.2026.100400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100400"}}